ASCO: New data highlights Vitrakvi safety and efficacy in NTRK gene fusion cancer

New data has been presented at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from three post-hoc subgroup analyses with German pharma major Bayer’s (BAYN: DE) Vitrakvi (larotrectinib).

Taken together, these highlight Vitrakvi’s long-term efficacy and safety profile in both adult and pediatric patients with solid tumors that have a NTR gene fusion without a known acquired resistance mutation, are metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or have progressed following treatment, according to investigators.

The first abstract showed that, in an expanded dataset (n=30) with longer follow-up, Vitrakvi demonstrated long-term efficacy and safety data in adult patients with advanced TRK fusion lung cancer, including those with CNS metastases (n=12). The results encourage wider adoption of next-generation sequencing (NGS) testing for identifying patients with solid tumors harboring NTRK gene fusions, including lung cancer. Among 27 adult patients eligible for IRC assessment with TRK fusion lung cancer enrolled, ORR was 74% (95% CI 54-89); 11% (n=3) complete responses and 63% (n=17) partial responses.